Home › Acute myeloïde leukemie › Michigan › Detroit
Acute myeloïde leukemie klinische studies in Detroit, MI
14 studies voor Acute myeloïde leukemie zoeken deelnemers op locaties in en rond Detroit (binnen ongeveer 30 mijl). Open een studie om te zien wie er kan deelnemen en hoe je contact opneemt met het studieteam.
Officiële studietekst (Engels)
Rekruteren voor een studie? Laat deze bovenaan deze pagina verschijnen — $99 voor 30 dagen →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
RekruterenFase 2
- Wayne State University/Karmanos Cancer Institute, Detroit
- Henry Ford Hospital, Detroit
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RekruterenObservatieonderzoekGezonde vrijwilligers welkom
- Henry Ford Hospital, Detroit
- Henry Ford Health Saint John Hospital, Detroit
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
RekruterenFase 3
- Henry Ford Health System, Detroit
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
RekruterenFase 2
- Henry Ford Hospital, Detroit
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
RekruterenFase 2
- Wayne State University/Karmanos Cancer Institute, Detroit
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RekruterenFase 1/2
- Children's Hospital of Michigan, Detroit
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
RekruterenFase 3
- Children's Hospital of Michigan, Detroit
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
RekruterenFase 3
- Wayne State University School of Medicine, Detroit
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
RekruterenFase 1
- Karmanos Cancer Institute, Detroit
- Henry Ford Cancer Institute, Detroit
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
RekruterenFase 3
- Henry Ford Cancer Institute, Detroit
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
RekruterenObservatieonderzoek
- Children's Hospital of Michigan, Detroit
- Henry Ford Health System, Detroit
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
RekruterenFase 2
- Karmanos Cancer Institute, Detroit
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
RekruterenFase 1
- Karmanos Cancer Institute, Detroit
HPC Offered for PRESERVE Expansion
RekruterenObservatieonderzoek
- Henry Ford Health, Detroit
Acute myeloïde leukemie studies in andere steden
- Houston, TX85 studies
- New York City, NY51 studies
- Boston, MA44 studies
- Seattle, WA41 studies
- Baldwin Park, CA40 studies
- Columbus, OH35 studies
- Philadelphia, PA34 studies
- Durham, NC33 studies
- Atlanta, GA31 studies
- Tampa, FL29 studies
- Chicago, IL26 studies
- Portland, OR25 studies
Andere studies in Detroit
- Niet-kleincellige longkanker44 studies
- Borstkanker33 studies
- Kanker (alle vormen)29 studies
- Colorectale kanker26 studies
- Eierstokkanker26 studies
- Metastatische kanker24 studies
- Prostaatkanker22 studies
- Endometriumkanker21 studies
- Longkanker20 studies
- Multipel myeloom19 studies
- Maagkanker16 studies
- Plaveiselcelcarcinoom van hoofd en hals15 studies
Van ClinicalTrials.gov, gegevens opgehaald op 6 okt. 2026. Elke studie stelt eigen deelnamecriteria vast; het studieteam bepaalt wie er kan deelnemen.